TYME TECHNOLOGIES, INC.
DelistedCIK 1537917fmd_0KHKZ7ZR0ZYV8F79PEMFCQN6XBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Mar 02, 2011 to Jun 30, 2022, 46 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | – | – | 1 | 4 | 6 | 9 | 15 | 13 | 17 | 13 |
| Total operating expenses | 0 | 0 | 3 | 9 | 15 | 19 | 32 | 26 | 27 | 26 |
| Operating income | – | – | (3) | (9) | (15) | (19) | (32) | (26) | (27) | (26) |
| Interest expense | – | – | 0 | 4 | – | – | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | 0 | 0 | 0 | – |
| Other non-operating income (expense) | – | – | – | 0 | – | 0 | (1) | 4 | (2) | 2 |
| Income before taxes | – | (0) | (3) | (12) | (15) | (19) | (33) | (22) | (29) | (24) |
| Income tax expense | – | – | – | – | 0 | 0 | – | – | – | – |
| Net income from continuing operations | – | – | – | – | (15) | (19) | – | – | – | – |
| Net income | – | (0) | (3) | (12) | (15) | (19) | (33) | (22) | (29) | (24) |